The metabolic disorders drugs market comprises of sale of metabolic disorders& drugs and associated to services provided by organisations that produce drugs to cure metabolic disorders diseases. The metabolic disorders occur due to disruption of chemical processes and changes occurring in the cells and fluids of the body. Moreover such disorder is based mainly on the defects associated with the enzyme, process in the body that are controlled by enzymes. Any such disruption in the pathways also involved over the development and metabolism of carbohydrates, proteins, fats, and nucleic acids, further results in development of the metabolic disorders. The diabetes has now become a global epidemic with almost more than 5% of the population is now affected by disease. Further disease also requires constant medication in order to battle fatal conditions.
According to report “Metabolic Disorders Drugs Global Market Report 2019” Some of the key companies operating in the market include Novo Nordisk A/S, Sanofi S.A., Boehringer Ingelheim GmbH, Eli Lilly and Company, Merck KgaA; Amgen, Inc., AstraZeneca PLC, Actelion Pharmaceuticals Ltd., Shire PLC, AbbVie Inc., Biocon Ltd., BioMarin Pharmaceutical, Inc., Bristol-Myers Squibb Company; Cipla, Inc., and CymaBay Therapeutics, Inc. Expansion of product portfolios and M&A are the key strategies undertaken by most of these companies.
Based on disease, metabolic disorders drugs market is categorized into diabetes, lysosomal disorders, hypercholesterolemia, obesity, and inherited metabolic disorders. These diseases are mostly inherited from the older generation through a faulty gene and some show immediate effect like the lysosomal disorders, while some show up later due to aging. Based on type, market is segmented into anti Diabetics drugs, anti-thyroid drugs and others. Based on distribution channel market is segmented into hospital pharmacies. Based on retail pharmacies/ drug stores and others. Based on by route of administration market is segmented into oral, parenteral and others. Based on drug classification market is segmented into branded drugs, generic drugs. Based on mode of purchase market are segmented into prescription-based drugs and over-the-counter drugs
Based on route of administration, the market is segmented into oral, parenteral and other routes of administration. Oral route of administration segment is the major revenue-generating segment with the wide usage in diabetes and hypercholesterolemia treatments. The rise in demand for the safe and smart drug delivery have also driven the growth in the segment owing to ease of use, reliability, and proven results further offers oral route of the administration.
Based on geography the North American region is the largest region with the metabolic disorders drugs market, that accounted for more than half of the global market. The Asia Pacific region is the second largest region accounted for one-fourth of the global metabolic disorders drugs market. The Africa held the smallest share in geography segment in the metabolic disorders drugs market. The North America was dominant region owing to presence of some of the major companies. The increase in prevalence of the obesity and diabetes in the region is yet another factor which accountable for the largest share. The increase in healthcare expenditure coupled with rising awareness about the metabolic disorders is expected to drive the regional market substantially over the forecast period.
For More Information, click on the link below:-
Ankur Gupta, Head Marketing & Communications